Jefferies Lowers Estimates on Nanosphere

Jun 22, 2011

NEW YORK (GenomeWeb News) – Investment firm Jefferies on Tuesday lowered its revenue and price targets for Nanosphere, following the US Food and Drug Administration's denial of a marketing application for its Plavix (clopidogrel) metabolism test.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Here We Are Again

American scientists find themselves once again warning the Trump administration not to dismiss science, the New Yorker report.

In the Pink

A new study suggests CRISPR could be used to save coral reefs from dying off, Forbes reports.

All Tied Up in a Bow

Researchers have found that the i-motif shape of DNA previously observed in the lab also exists in human cells, and that it may serve a purpose.

This Week in PNAS

In PNAS this week: a genomic, transcriptomic, and metabolomic analysis of the tea plant, Arabidopsis thaliana's adaptations to specific local environments, and more.

Featured White Papers

The Foundry Model is Coming to Molecular Diagnostics, Courtesy of the Semiconductor Industry

Combined Analysis of CNVs and SNVs in Genomic Diagnostics

May

15

Featured Webinar

Reaping the Benefits of Algorithm-Driven Research in Synthetic Biology

This webinar will discuss how an algorithm-driven synthetic biology system can enable engineering of biological systems for a range of applications.

Jun

20

Featured Webinar

Expert Tips on Sequencing and Library Prep from the Wellcome Sanger Institute

In this webinar, Michael Quail of the R&D Sequencing team at the Wellcome Trust Sanger Institute will provide an expert perspective on library prep for next-generation sequencing.

Jun

28

Featured Webinar

An Optimized NGS Workflow for Human Metagenomic Analysis

This webinar will review a standardized, high-throughput, and fully automated library prep protocol for human metagenomic analysis.

Main menu